Dyne Therapeutics Inc (NASDAQ:DYN) — Market Cap & Net Worth
Market Cap & Net Worth: Dyne Therapeutics Inc (DYN)
Dyne Therapeutics Inc (NASDAQ:DYN) has a market capitalization of $2.96 Billion ($2.96 Billion) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4968 globally and #1672 in its home market, demonstrating a -26.28% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dyne Therapeutics Inc's stock price $17.90 by its total outstanding shares 165313796 (165.31 Million). Also see Dyne Therapeutics Inc asset portfolio for a full breakdown of the balance sheet.
Dyne Therapeutics Inc Market Cap History: 2020 to 2026
Dyne Therapeutics Inc's market capitalization history from 2020 to 2026. Data shows change from $3.47 Billion to $2.96 Billion (-4.71% CAGR). Also see DYN cash flow metrics for how efficiently the company converts equity into cash flow.
Index Memberships
Dyne Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.11% | #131 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.01% | #559 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.16% | #83 of 263 |
Weight: Dyne Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Dyne Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dyne Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Dyne Therapeutics Inc share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of DYN by Market Capitalization
Companies near Dyne Therapeutics Inc in the global market cap rankings as of September 16, 2026. Review Dyne Therapeutics Inc tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Dyne Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Dyne Therapeutics Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Dyne Therapeutics Inc's market cap moved from $3.47 Billion to $ 2.96 Billion, with a yearly change of -4.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.96 Billion | -8.49% |
| 2025 | $3.23 Billion | -16.98% |
| 2024 | $3.89 Billion | +77.14% |
| 2023 | $2.20 Billion | +14.75% |
| 2022 | $1.92 Billion | -2.52% |
| 2021 | $1.97 Billion | -43.38% |
| 2020 | $3.47 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Dyne Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.96 Billion USD |
| MoneyControl | $2.96 Billion USD |
| MarketWatch | $2.96 Billion USD |
| marketcap.company | $2.96 Billion USD |
| Reuters | $2.96 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Dyne Therapeutics Inc
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal mus… Read more